Early Amantadine Treatment Reduces the Risk of Death in Patients With Large Hemisphere Infarctions

Jie Li
https://orcid.org/0000-0001-9575-4232

Ping Zhang
Department of Neurology, people's hospital of Deyang City

Yingying Liu
Department of Neurology, people's hospital of Deyang City

Simiao Wu
Center of Cerebrovascular disease, Department of Neurology, West China hospital

Xingyang Yi
Department of Neurology, people's hospital of Deyang City

Shihong Zhang
Center of cerebrovascular disease, Department of Neurology, West China hospital

Chun Wang (✉ dysmyysjnkw@163.com )
Department of Neurology, people's hospital of Deyang City

Ming Liu
Center of cerebrovascular disease, Department of Neurology, West China hospital

Research article

Keywords: amantadine hydrochloride, large hemispheric infarction, propensity score matching, outcome

DOI: https://doi.org/10.21203/rs.3.rs-35510/v1

License: ☛ Ⓚ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Objective

Amantadine hydrochloride is one of the most frequently prescribed drugs for patients with severe traumatic brain injury in restoring consciousness and accelerating the pace of functional recovery. However, there is a paucity of studies on the effectiveness of amantadine in patients with severe stroke especially large hemisphere infarction (LHI). The present study aimed to investigate whether amantadine treatment is associated with better clinical outcomes in conservatively treated LHI patients.

Methods

We retrospectively collected conservatively treated LHI patients according to inclusion/exclusion criteria. The patients were divided into two groups based on the treatment regimen, whether they did receive amantadine hydrochloride in addition to standard therapy (ST) or not. The primary outcomes were in-hospital death, 3-month mortality and unfavorable outcome (defined as modified Rankin Scale score of 4 to 6). All outcomes were compared between the two groups before and after propensity score matching (PSM). Multivariate logistic regression was performed to identify the association between early amantadine hydrochloride treatment and clinical outcomes in LHI patients.

Results

31 LHI patients treated with amantadine combined with ST and 127 patients treated with ST were enrolled. Amantadine group had a shorter prehospital delay (median: 2 vs. 10 hours), higher baseline NIHSS score (21.71 ± 4.76 vs. 17.49 ± 5.84) and higher rate of dominant hemisphere involvement (67.74% vs. 45.67%). After PSM, amantadine treatment significantly reduced the risk of in-hospital death (7.41% vs. 31.11%, \( p < 0.019 \)) and 3-month mortality (25.93% vs. 55.56%, \( p < 0.008 \)). Amantadine treatment yielded a significant decrease in death in-hospital (before PSM: OR 0.143, 95% CI 0.034 to 0.605; after PSM: OR 0.113, 95% CI 0.020 to 0.635) and 3-month mortality (before PSM: OR 0.214, 95% CI 0.077 to 0.598; after PSM: OR 0.176, 95% CI 0.053 to 0.586) in unmatched and matched multivariable analysis.

Conclusion

The results of our study provide initial evidence that early amantadine treatment was associated with a decrease in death in conservatively treated LHI patients. Considering the limitations of observational study, randomized controlled trials with large sample size may help provide a clearer picture of the utility of amantadine in LHI patients.

Methods
Large hemispheric infarction (LHI), which usually caused by occlusion of the internal carotid artery or proximal middle cerebral artery (MCA), constitutes up to 10% of supratentorial ischemic strokes. It is a widely accepted devastating condition with a high mortality rate of approximately 80% in two intensive care-based series. Up to now, no pharmacological strategies have been proven effective by clinical trials. Decompressive hemicraniectomy (DHC) conducted within 48 hours after symptom onset has been proven effective for LHI patients with malignant course. However, only 0.3% of highly selected ischemic stroke patients would be eligible for DHC based on the strict eligibility criteria in the DHC trials. Although lack of evidence, many neuropharmacological therapies are still used off-label due to the lack of effective treatment in conservatively treated LHI patients.

Amantadine was first synthesized more than 50 years ago and initially developed as an antiviral agent. Further work has demonstrated the effectiveness of amantadine as an anti-parkinsonism agent, as well as a treatment option for neuroleptic-induced extrapyramidal symptoms and neuroleptic malignant syndrome. Amantadine hydrochloride is one of the most frequently prescribed drugs for patients with prolonged impaired consciousness after traumatic brain injury (TBI). The mechanism of action of amantadine is still not fully understood but it is thought to act as an N-methyl-D-aspartate (NMDA) receptor antagonist increasing dopamine synthesis and release in the striatum. Sufficient synaptic dopamine levels are necessary for many physiological functions including motivation, motor control, emotion, and cognitive processing. The result of a small sample randomized trial in patients with TBI-associated diffuse axonal injury suggested that amantadine was effective in improving neuro-recovery and it was well tolerated at a dosage of 200 mg/day with no serious adverse side effects. In a multicenter trial, amantadine at doses of 200-400 mg/day has successfully been demonstrated effective and safe in accelerating the pace of functional recovery in patients with severe TBI. A clinical-experimental study conducted in Russian reported that amantadine exhibited significant restoration of consciousness and better regress of neurological deficit in the first day of ischemic stroke.

So far, there is a lack of studies investigating amantadine for the treatment of patients with non-traumatic brain injuries such as severe stroke. The present study aimed to explore whether amantadine treatment is associated with better clinical outcomes in conservatively treated LHI patients.

**Methods**

**Study design and subjects**

From February 2012 to January 2015, we retrospectively and consecutively enrolled acute ischemic stroke patients admitted to the Department of Neurology, People's Hospital of Deyang City. LHI was defined as an infarction involving more than 50% of the territory of the MCA in computed tomography (CT) and/or magnetic resonance imaging (MRI), no matter the involvement of the adjacent territories. All patients completed brain CT before initial treatment. A second CT or MRI was performed within the first 7 days of hospitalization. Other CT scans were performed if patients suffered neurological...
deterioration, to identify brain edema or hemorrhagic transformation. Patients who met the following inclusion criteria were eligible for the present study: (1) age ≥ 18 years, (2) LHI patients admitted to hospital within 24 hours of symptom onset. Patients were excluded if they met one of the following exclusion criteria: (1) received DHC during hospitalization; (2) prior treatment with amantadine; (3) history of severe renal disease; (4) history of epilepsy with more than one seizure in the previous month; (5) pregnancy; (6) incomplete hospital records or missing imaging that would prevent complete data collection; (7) any disability related to the central nervous system that predated the stroke; and (8) with a premorbid modified Rankin Scale (mRS, a scale of 0 to 6, with 0 indicating no symptoms and 6 indicating death) score of more than 2 and lived dependently.

All LHI patients were treated with standard therapy (ST), including mechanical ventilation in maintaining a patent airway, head position, glucose, blood pressure and temperature management, parenteral and enteral feeding, osmotic therapy for brain edema, antibiotics, and other symptomatic treatment measures for stroke-related complications. A persistent impaired consciousness was the main reason for amantadine hydrochloride treatment. Early amantadine treatment in LHI patients was defined as amantadine hydrochloride initiated within 24 hours after stroke onset and continuing for at least three days. Amantadine hydrochloride was added at an oral dose of 100 mg twice daily. According to whether they did receive amantadine or not, the patients were divided into two groups: the amantadine group (amantadine combined with ST) and the ST group.

The study protocol was approved by the Ethics Committee of the people's hospital of Deyang city (approval No. 2011-04-134). We obtained informed consent from all patients or their legal representative if the patient lost the capacity to give informed consent before they were enrolled, for using the patient's data for research.

Data collection

A standardized structured form was used to collect the following data: patient demographics, prehospital delay, baseline blood pressure and serum glucose, baseline National Institutes of Health Stroke Scale (NIHSS) score and Glasgow coma scale (GCS) score, vascular risk factors, diagnostic tests, neurological imaging, in-hospital treatment, and stroke-related complications during hospitalization. Detailed methods for data collection have been described in our previous study. The potential stroke etiology of LHI was categorized as large-artery atherosclerosis, cardio-embolism, stroke of other determined etiology and stroke of undetermined etiology based on the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria. In-hospital treatments analyzed in our study included thrombolysis, mechanical ventilation, osmotic agents (such as mannitol). Stroke-related complications, including both neurological and medical complications during hospitalization, were reviewed from hospital records when the patient was discharged by data collectors who were not aware of the study, which has been elaborated upon in our previous study.

Outcome measurement
Patients were followed up at 3-month after stroke onset via telephone interview or letter inquiries using questionnaires. The primary outcomes were in-hospital death, 3-month mortality and 3-month unfavorable outcome (defined as an mRS score of 4 to 6)\textsuperscript{20}. The secondary outcomes were stroke-related complications and adverse side effects recorded due to exposure to amantadine, including hypotension, livedo reticularis, seizure, hallucinations, etc.

**Statistical analyses**

All statistical analysis was performed using SPSS v22.0 (SPSS, Chicago, IL). Continuous variables are presented as means with standard deviations or median with range. Categorical variables are presented as frequencies with percentages. Intergroup differences in categorical variables were assessed for significance using the $c^2$ tests or Fisher's exact tests, while differences in continuous variables were assessed using Student's t-tests or the Mann-Whitney U test.

We performed a propensity score matching (PSM) algorithm including baseline characteristics that is assumed to be related to amantadine treatment via using multivariable logistic regression model, to calculate the propensity score (PS) for each patient. Then the LHI patients in the amantadine group were matched with the ST group by using the nearest neighbor approach (caliper 0.2, ratio 1:2) to minimize potential imbalances in the distribution of potential confounders between amantadine users and nonusers as previously described in detail\textsuperscript{27}.

Univariate analysis was performed to test variables that may affect the outcomes. Multivariate logistic regression analyses were further performed to explore the association between amantadine treatment with in-hospital death, 3-month mortality and unfavorable outcomes, by using the forced entry method adjusting for variables with $p<0.1$ in univariate analyses. All analyses were repeated following PSM. 3-month survival was estimated by the Kaplan-Meier method and a log-rank test was used for survival comparisons in the final matched dataset. The 95% confidence intervals (CI) were calculated to describe the precision of the estimates. Two-sided $P<0.05$ was considered to be statistically significant.

**Data availability**

The data that support the findings of this study are available from the corresponding author on reasonable request.

**Results**

During the 3-year study period, a total of 1574 acute ischemic stroke patients were screened. None of the patients administered intra-arterial revascularization procedures. We excluded 1416 patients. Finally, 31 LHI patients treated with amantadine combined with ST and 127 patients treated with ST were recruited to the current study. A flow diagram of included and excluded patients is provided in the Figure 1.
The baseline characteristics of LHI patients between groups are presented in Table 1. Patients treated with amantadine had a shorter prehospital delay (median: 2 vs. 10 hours, \( p<0.001 \)), a higher baseline NIHSS score (21.71±4.76 vs. 17.49±5.84, \( p<0.001 \)) and higher rate of dominant hemisphere involvement (67.74% vs. 45.67%, \( p=0.028 \)). The two groups did not differ in age, sex, baseline GCS score, baseline blood pressure and serum glucose, vascular risk factors, and stroke etiology (all \( p>0.05 \)).

After PS-matching, we identified two subgroups of 72 LHI patients that were balanced for all baseline characteristics, including 27 treated with amantadine combined with ST and 45 treated with ST. Relative multivariate imbalance in the form of the L1 measure was smaller (0.463 vs. 0.649) and no covariate had standardized mean differences of greater than 0.1 after PSM. Supplemental figure 1 also showed that covariate balance was massively improved in the matched dataset. As shown in Table 2, there was no significant difference in the baseline characteristics between groups in the matched dataset (all \( p>0.05 \)).

For the acute phase treatment of LHI, the two groups did not differ in receiving thrombolysis, mechanical ventilation and osmotic agents before and after PSM (all \( p>0.05 \), Table 3). The mean duration of amantadine treatment was 28.71 days before PSM and 30.96 days after PSM. Outcomes of LHI patients between groups are shown in Table 3 and Table 4.

**The primary outcomes**

**In-hospital death:**

Before PSM, LHI patients treated with amantadine did not show a significantly lower rate of in-hospital death (9.68% vs. 21.26%, \( p=0.132 \)). However, amantadine treatment significantly reduced the risk of in-hospital death after PSM (7.41% vs. 31.11%, \( p=0.019 \)).

After adjusting for age, sex, baseline NIHSS score and serum glucose on admission, the multivariable analysis yielded a significant decrease in death in-hospital (OR 0.143, 95 % CI 0.034 to 0.605 before PSM and OR 0.113, 95 % CI 0.020 to 0.635 after PSM, respectively, both \( p<0.05 \)).

**3-month mortality**

At 3 months, 1.2% (2/158) patients were lost to follow-up, both were in the ST group. Before PSM, LHI patients treated with amantadine did not show a significantly lower rate of 3-month mortality (29.03% vs. 40.16%, \( p=0.228 \)). However, amantadine treatment reduced the risk of 3-month mortality after PSM (25.93% vs. 55.56%, \( p=0.008 \)). 3-month survival was estimated by the Kaplan-Meier method and identified that amantadine was associated with a significantly higher 3-month survival rate (\( p<0.020 \), log-rank test, Figure 2).

After adjusting for age, sex, baseline NIHSS score, the multivariable analysis yielded a significant decrease in 3-month mortality (OR 0.214, 95 % CI 0.077 to 0.598 before PSM and OR 0.176, 95 % CI 0.053 to 0.586 after PSM, respectively, both \( p<0.05 \)).
3-month unfavorable outcomes

Amantadine treatment was not associated with a significantly lower rate of 3-month unfavorable outcomes before and after PSM, no matter in univariable or multivariable analysis (all \( p \leq 0.05 \)). Nevertheless, 11 (25.6%) patients in the amantadine group and 11 (40.7%) in the ST group had an mRS score \( \leq 3 \) after PSM, which suggested a nonsignificant trend towards 3-month favorable outcomes in those LHI patients treated with amantadine (Supplemental figure 2).

The secondary outcome

Before PSM, the amantadine group had a significantly higher rate of brain edema (93.55% vs. 31.50%, \( p < 0.001 \)), hemorrhagic transformation (45.16% vs. 24.41%, \( p = 0.022 \)) and pneumonia (83.87% vs. 63.78%, \( p = 0.009 \)). However, the two groups did not differ in all stroke-related complications after PSM (all \( p > 0.05 \)). It is worth noting that the amantadine group did not have a higher rate of seizures before and after PSM.

Amantadine hydrochloride was well tolerated at a dosage of 200 mg/day throughout the study. There were no serious adverse side effects recorded due to exposure to amantadine. No patients experienced discontinuation of medication or change in dosage throughout the study because of side effects.

Discussion

The present study determined whether amantadine treatment is associated with better clinical outcomes in conservatively treated LHI patients. To the best of our knowledge, this is the first study to investigate the treatment with amantadine for severe stroke. The results suggested that early amantadine treatment was associated with significantly lower rates of in-hospital and 3-month death and nonsignificant trend of favorable outcomes in conservatively treated LHI patients. In our study, totally 30 patients died during hospitalization and 60 patients died at 3-month follow-up. The most common cause of 3-month death was brain herniation in both groups (6 patients in the amantadine group and 26 patients in the ST group), followed with pneumonia (3 patients in the amantadine group and 13 patients in the ST group). For financial concerns, religious and values, some critically ill patients were given up treatment by their family members and died within a few days after discharge especially those patients from rural areas. In the present study, 6 patients in the amantadine group and 24 patients in the ST group died after discharge, however, among those patents, 5 (83.33%) in the amantadine group and 10 (41.47%) in the ST group had withdrawal of care. Thus, our results could not be explained by that amantadine resulted in more wakefulness then perhaps families would have withdrawn care less often making it appear that amantadine resulted in lower mortality. Meanwhile, most of the survivors with severe disability were taken home directly or opted for hospice care, rather than seeking for further speech therapy and physiotherapy, which could explain why the follow-up data from LHI patients recovering from such a devastating condition are so close to their discharge\(^2\).

Stroke is the second most common cause of death worldwide and the leading cause of death in China\(^2\). Ischemic stroke, which accounts for approximately 80% of all strokes, is a serious disease with a complex
pathophysiology. Various agents that may interfere with each step of the ischemic cascade can, in theory, be developed as a candidate for stroke treatment. Two major strategies have been developed to treat ischemic stroke: recanalization (including thrombolysis and mechanical thrombectomy) and neuroprotection. During the last three decades, thousands of neuroprotective agents have been tested in animal models with reports of experimental efficacy, and nearly 200 neuroprotection clinical trials are ongoing or have been completed, but none has been proven effective in clinical trials. Despite the failure of most neuroprotective drugs, neuroprotection has never been abandoned especially with the help of improved preclinical testing and clinical trial design.

LHI, which usually results from failure in valid recanalization of occlusion of the internal carotid artery or proximal MCA, is a devastating disease with high mortality rate. Although DHC has been proven to benefit LHI patients with malignant course, only highly selected patients younger than 60 years of age would be eligible for DHC. Until recently, no pharmacological strategies have been proven effective by clinical trials. Although lack of evidence, many neuropharmacological therapies are still used off-label in clinical practice due to the lack of effective treatment in conservatively treated LHI patients.

In the present study, we found that early amantadine treatment was associated with a significantly lower death rate and nonsignificant trend of favorable outcomes in conservatively treated LHI patients. These results are similar to a clinical-experimental study that was carried out in acute ischemic stroke patients in Russian and reported that amantadine sulfate (PK-Merz) exhibited significant restoration of consciousness and better regress of neurological deficit in the first hours of ischemic stroke. There are two main reasons for the effects of amantadine. First, amantadine has profound NMDA receptor antagonist effects, which may contribute to its neuroprotective effects when administered in the first several hours or days after brain injury. It is theorized that it can block the activation of glutamate receptors and other NMDA channels to inhibit the elevation of intracellular Ca$^{2+}$ levels. Excess of intracellular Ca$^{2+}$ plays a unique role in the ischemic pathophysiology by activation of a variety of Ca$^{2+}$ dependent enzymes, leading to irreversible mitochondrial damage, inflammation, cytotoxic edema, necrotic and programmed cell death. Second, amantadine may promote dopaminergic activity by facilitating presynaptic release and blocking postsynaptic reuptake, which is related to the enhancement of endogenous recovery mechanisms. The favorable functional consequences of amantadine may reflect the strengthening of neurotransmission in the dopamine-dependent nigrostriatal, mesolimbic, and frontostriatal circuits that are responsible for mediating arousal, drive, attentional, and cognitive functions. A systematic review concluded that improvement in arousal and cognitive function had been observed in patients with TBI when amantadine was initiated 3 days to 5 months after brain injury. Two case studies using positron emission tomography to evaluate the effects of amantadine on chronic TBI showed that amantadine treatment would result in arousal and executive function improvement and a significant increase in prefrontal cortical metabolism and a nonsignificant increase in striatal D2 dopamine-receptor availability. Results of the above studies support the role of amantadine in enhancing neurological rehabilitation through the dopaminergic system independent of its
neuroprotective effects. In a multicenter trial, amantadine with a treatment duration of 4 weeks has successfully been demonstrated effective and safe in accelerating the pace of functional recovery in patients with severe TBI, and the investigator of the trial indicated that the response of amantadine is drug-dependent\textsuperscript{17}. In our study, the mean duration of amantadine treatment was 28.71 days before PSM and 30.96 days after PSM, however, we did not find a significant effect in 3-month functional outcome. Since amantadine has the dual effect of neuroprotection and recovery enhancement, it is reasonable to choose a treatment duration of 4 weeks or longer in future research.

The seizure is a side effect of the biggest concern to clinicians when treating LHI patients with amantadine. However, poststroke seizures are not frequent in LHI patients with an incidence rate of 7.0% in our previous study\textsuperscript{26}. In our study, LHI patients treated with amantadine did not suffer a higher rate of seizures before and after PSM. Amantadine's effect on the seizure threshold is dose-dependent. It has been demonstrated that lower doses of amantadine may elevate the seizure threshold, while high doses (greater than 400 mg/day in adults) may induce seizures\textsuperscript{41}. Similar dosages of amantadine to our study even may be an effective alternative treatment for some types of seizures\textsuperscript{42,43}, which most likely results from its NMDA receptor antagonist effects\textsuperscript{44}.

**Limitations**

The present study has several limitations, so our results should be interpreted with caution. First, it was a single tertiary hospital-based study, so the results may not represent the whole population. Some patients with severe stroke might not be hospitalized, especially those who died before hospitalization, so we could not exclude inclusion bias. Second, it was a retrospective study, so we could not control the duration of amantadine and other combination therapy. Although it was not a randomized study, we performed a PSM analysis to minimize potential imbalances between groups on baseline characteristics. Third, the sample size of the amantadine group was relatively small and reduced the likelihood of finding significant effects. Fourth, although we did not calculate and compare the infarct volume that is critical to the outcomes of LHI patients, PSM analysis was performed to make the baseline NIHSS score balanced between groups in the current study. Fifth, we only conducted follow-up at a single time point of three months. Meanwhile, follow-up in our study was conducted via telephone interview or mailed questionnaire instead of a clinical visit, which may increase the risk of reporting bias. Finally, we did not use continuous electroencephalography routinely to detect seizures. However, a high incidence of amantadine induced subclinical seizures would be expected to lead to more unfavorable outcomes.

**Conclusion**

The results of our study provide initial evidence that early amantadine treatment was associated with a significantly lower death rate and nonsignificant trend of favorable outcomes in conservatively treated LHI patients. Considering the limitations of observational study, randomized controlled trials with large sample size may help provide a clearer picture of the utility of amantadine in LHI patients.
Abbreviations

LHI: large hemispheric infarction; ST: standard therapy; PS: propensity score; PSM: propensity score matching; DHC: decompressive hemicraniectomy; MCA: middle cerebral artery; TBI: traumatic brain injury; NMDA: N-methyl-D-aspartate; CT: computed tomography; MRI: magnetic resonance imaging; mRS: modified Rankin Scale; NIHSS: National Institutes of Health Stroke Scale; GCS: Glasgow coma scale; TOAST: Trial of Org 10172 in Acute Stroke Treatment; OR: odds ratio; CI: confidence interval.

Declarations

Acknowledgments

Not applicable.

Authors' Contributions

JL, PZ - conceived the study, collected, analyzed and interpreted the data, as well as drafted the manuscript.

JL, YL, SW, XY - participated in statistical analysis, data interpretation and revised the manuscript.

CW, ML - contributed substantially to study design and supervision, data interpretation and manuscript writing.

All authors critically revised the manuscript for important intellectual content and approved the final manuscript.

Funding

This research was funded by Universal Application Program, Health and Family Planning Commission of Sichuan Province in China (17PJ084), Key Research and Development Program, Science and Technology Department of Sichuan Province in China (NO.2017SZ0007) and National Natural Science Foundation of China (NO. 81974181).

Availability of data and materials

All relevant data are included in the manuscript. The individual data collected for each participant in our study cannot be provided in order to protect the participants’ identity.

Ethics approval and consent to participate

The study protocol was submitted to and approved by the Ethics Committee of People's Hospital of Deyang City (Reference No. 2011-04-134). Written informed consent was obtained from all patients.
before they were enrolled, or from their legal proxies if the patient lost capacity to give the consent.

Consent to publish

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Huttner HB, Schwab S. Malignant middle cerebral artery infarction: clinical characteristics, treatment strategies, and future perspectives [J]. Lancet Neurol. 2009;8(10):949–58.
2. Hacke W, Schwab S, Horn M, Spranger M, De Georgia M, von Kummer R. 'Malignant' middle cerebral artery territory infarction: clinical course and prognostic signs [J]. Arch Neurol. 1996;53:309–15.
3. Berrouschot J, Sterker M, Bettin S, Ko¨ster J, Schneider D. Mortality of space-occupying ('malignant') middle cerebral artery infarction under conservative intensive care[J]. Intensive Care Med. 1998;24:620–3.
4. Treatment options for large hemispheric stroke [J]
   Steiner T, Ringleb P, Hacke W. Treatment options for large hemispheric stroke [J]. Neurology, 2001, 57(suppl 2): 61–8.
5. Vahedi K, Hofmeijer J, Juettler E, et al. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials[J]. Lancet Neurol. 2007;6(3):215–22.
6. Rahme R, Curry R, Kleindorfer D, et al. How often are patients with ischemic stroke eligible for decompressive hemicraniectomy? [J]. Stroke. 2012;43(2):550–2.
7. Davies WL, Grunert RR, Haff RF, et al. Antiviral activity of 1-adamantanamine (amantadine)[J]. Science. 1964;144(3620):862–3.
8. Schwab RS, England AC, Poskanzer DC, et al. Amantadine in the treatment of Parkinson's disease[J]. Jama. 1969;208(7):1168–70.
9. Parkes JD, Calver DM, Zilkha KJ, et al. Controlled trial of amantadine hydrochloride in Parkinson's disease[J]. The Lancet. 1970;295(7641):259–62.
10. Gelenberg AJ, Mandel MR. Catatonic reactions to high-potency neuroleptic drugs[J]. Arch Gen Psychiatry. 1977;34(8):947–50.
11. DiMascio A, Bernardo DL, Greenblatt DJ, et al. A controlled trial of amantadine in drug-induced extrapyramidal disorders[J]. Arch Gen Psychiatry. 1976;33(5):599–602.
12. Kornhuber J, Weller M. Amantadine and the glutamate hypothesis of schizophrenia Experiences in the treatment of neuroleptic malignant syndrome[J]. Journal of Neural Transmission/General Section JNT. 1993;92(1):57–65.
13. Whyte J, Katz D, Long D. Predictors of outcome and effect of psychoactive medications in prolonged posttraumatic disorders of consciousness: a multicenter study[J]. Arch Phys Med Rehabil. 2005;86(3):453–62.

14. Peeters M, Page G, Maloteaux JM, et al. Hypersensitivity of dopamine transmission in the rat striatum after treatment with the NMDA receptor antagonist amantadine[J]. Brain research. 2002;949(1–2):32–41.

15. Bales JW, Wagner AK, Kline AE, et al. Persistent cognitive dysfunction after traumatic brain injury: a dopamine hypothesis[J]. Neuroscience Biobehavioral Reviews. 2009;33(7):981–1003.

16. Meythaler JM, Brunner RC, Johnson A, et al. Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial[J]. J Head Trauma Rehabil. 2002;17(4):300–13.

17. Giacino JT, Whyte J, Bagiella E, et al. Placebo-controlled trial of amantadine for severe traumatic brain injury[J]. N Engl J Med. 2012;366(9):819–26.

18. Khasanova DR, Saikhunov MV, Kitaeva EA, et al. Amantadine sulfate (PK-Merz) in the treatment of ischemic stroke: a clinical-experimental study[J]. Zhurnal nevrologii i psikhiatrii imeni SS Korsakova. 2009;109(5 Suppl 2):37–43.

19. Uhl E, Kreth FW, Elias B, et al. Outcome and prognostic factors of hemicraniectomy for space occupying cerebral infarction [J]. J Neurol Neurosurg Psychiatry. 2004;75:270–4.

20. de Haan R, Limburg M, Bossuyt P, van der Meulen J, Aaronson N. The clinical meaning of Rankin ‘handicap’ grades after stroke [J]. Stroke. 1995;26:2027–30.

21. Wijdicks EFM, Sheth KN, Carter BS, et al. Recommendations for the management of cerebral and cerebellar infarction with swelling: a statement for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke. 2014;45(4):1222–38.

22. Cossu G. Therapeutic options to enhance coma arousal after traumatic brain injury: state of the art of current treatments to improve coma recovery[J]. Br J Neurosurg. 2014;28(2):187–98.

23. Li J, Zhang P, Wu S, et al. Factors associated with favorable outcome in large hemispheric infarctions [J]. BMC Neurol. 2018;18(1):152.

24. Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment [J]. Stroke. 1993;24(1):35–41.

25. Johnston KC, Li JY, Lyden PD, et al. Medical and neurological complications of ischemic stroke: experience from the RANTTAS trial [J]. Stroke. 1998;29(2):447–53.

26. Li J, Zhang P, Wu S, et al. Stroke-related complications in large hemisphere infarction: incidence and influence on unfavorable outcome [J]. Ther Adv Neurol Disord. 2019;12:1756286419873264.

27. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects[J]. Biometrika. 1983;70(1):41–55.
28. Wu S, Wu B, Liu M, et al. Stroke in China: advances and challenges in epidemiology, prevention, and management[J]. Lancet Neurol. 2019;18(4):394–405.
29. Sutherland BA, Minnerup J, Balami JS, et al. Neuroprotection for ischaemic stroke: translation from the bench to the bedside[J]. International Journal of Stroke. 2012;7(5):407–18.
30. Durukan A, Tatlisumak T. Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia[J]. Pharmacology Biochemistry Behavior. 2007;87(1):179–97.
31. O’Collins VE, Macleod MR, Donnan GA, et al. 1,026 experimental treatments in acute stroke[J]. Ann Neurol. 2006;59(3):467–77.
32. Stroke T, A I R. S. Recommendations for standards regarding preclinical neuroprotective and restorative drug development[J]. Stroke. 1999;30(12):2752.
33. Fisher M. New approaches to neuroprotective drug development[J]. Stroke. 2011;42(1_suppl_1):24–7.
34. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view[J]. Trends in neurosciences. 1999;22(9):391–7.
35. Fisher M, Schaebitz W. An overview of acute stroke therapy: past, present, and future[J]. Arch Intern Med. 2000;160(21):3196–206.
36. Gianutsos G, Chute S, Dunn JP. Pharmacological changes in dopaminergic systems induced by long-term administration of amantadine[J]. Eur J Pharmacol. 1985;110(3):357–61.
37. Feeney DM, Sutton RL. Pharmacotherapy for recovery of function after brain injury[J]. Crit Rev Neurobiol. 1987;3(2):135–97.
38. Sawyer E, Maura LS, Ohlinger MJ. Amantadine enhancement of arousal and cognition after traumatic brain injury[J]. Ann Pharmacother. 2008;42(2):247–52.
39. Kraus MF, Smith GS, Butters M, et al. Effects of the dopaminergic agent and NMDA receptor antagonist amantadine on cognitive function, cerebral glucose metabolism and D2 receptor availability in chronic traumatic brain injury: a study using positron emission tomography (PET)[J]. Brain Inj. 2005;19(7):471–9.
40. Schnakers C, Hustinx R, Vandewalle G, et al. Measuring the effect of amantadine in chronic anoxic minimally conscious state[J]. Journal of Neurology Neurosurgery Psychiatry. 2008;79(2):225–7.
41. Gualtieri T, Chandler M, Coons TB, Brown LT. Amantadine: A clinical profile for traumatic brain injury. Clin Neuropharmacol. 1989;12:258–70.
42. Drake JME, Pakalnis A, Denio LS, et al. Amantadine hydrochloride for refractory generalized epilepsy in adults[J]. Acta neurologica belgica. 1991;91(3):159–64.
43. Shahar EM, Brand N. Effect of add-on amantadine therapy for refractory absence epilepsy[J]. J Pediatr. 1992;121(5):819–21.
44. Zafonte RD, Lexell J, Cullen N. Possible applications for dopaminergic agents following traumatic brain injury: part 2[J]. J Head Trauma Rehabil. 2001;16(1):112–6.
Tables

Table 1. Baseline characteristics of LHI patients before PSM
|                                | Amantadine (n=31) | ST (n=127) | P value |
|--------------------------------|-------------------|------------|---------|
| **Age (years)**                |                   |            |         |
| Mean±SD                        | 70.68±11.42       | 65.45±15.32| 0.077*  |
| Median(range)                  | 76(46-87)         | 68(18-94)  | 0.061†  |
| Female, n (%)                  | 17(54.83)         | 69(54.33)  | 0.959‡  |
| Time from onset(hours), median(range) | 2(1-24)        | 10(1-24)   | <0.001† |
| NIHSS score on admission       | 21.71±4.76        | 17.49±5.84 | <0.001* |
| GCS score on admission         | 9.35±1.72         | 10.17±3.06 | 0.158*  |
| SBP on admission (mm Hg)       | 150.45±20.48      | 140.17±26.96| 0.056*  |
| DBP on admission (mm Hg)       | 87.71±14.95       | 82.87±16.84| 0.145*  |
| Serum glucose on admission (mmol/L) | 7.72±4.49     | 7.88±3.25  | 0.822*  |
| **Risk factors, n (%)**        |                   |            |         |
| Hypertension                   | 12(38.71)         | 66(51.97)  | 0.186‡  |
| Diabetes mellitus              | 6(19.35)          | 27(21.26)  | 0.815‡  |
| Dyslipidemia                   | 6(19.35)          | 20(15.75)  | 0.627‡  |
| Coronary heart disease         | 8(25.81)          | 21(16.54)  | 0.232‡  |
| Atrial fibrillation            | 22(70.97)         | 70(55.12)  | 0.109‡  |
| Rheumatic heart disease        | 5(16.13)          | 35(27.56)  | 0.189‡  |
| Current smoking                | 10(32.26)         | 26(20.47)  | 0.161‡  |
| Alcohol consumption            | 3(9.68)           | 19(14.96)  | 0.446‡  |
| Previous all strokes/TIA       | 9(29.03)          | 26(20.47)  | 0.304‡  |
| Previous IS                    | 8(25.81)          | 18(14.17)  | 0.117‡  |
| Previous ICH                   | 1(3.23)           | 4(3.15)    | 0.983‡  |
| Previous TIA                   | 0(0)              | 4(3.15)    | 0.716‡  |
| **Stroke in dominant hemisphere, n (%)** | 21(67.74)       | 58(45.67)  | 0.028‡  |
| **TOAST classification, n (%)**|                   |            | 0.572‡   |
| Large-artery atherosclerosis   | 5(16.13)          | 32(25.20)  |         |
| Cardio-embolism                | 23(74.19)         | 77(60.63)  |         |
| Etiology                  | PSM | ST  |
|--------------------------|-----|-----|
| Other determined etiology| 1(3.23) | 7(5.51) |
| Undetermined etiology    | 2(6.45) | 11(8.66) |

Abbreviations: PSM = propensity score matching; ST = standard therapy; SBP = systolic blood pressure; DBP = diastolic blood pressure; NIHSS = National Institutes of Health Stroke Scale; GCS = Glasgow Coma Scale; TIA = transit ischemic attack; IS = ischemic stroke; ICH = intracerebral hemorrhage.

*Student t test. †Mann–Whitney U test. ‡χ² test.

**Table 2:** Baseline characteristics of LHI patients after PSM
|                                      | **Amantadine** (n=27) | **ST** (n=45) | **P value** |
|--------------------------------------|------------------------|----------------|-------------|
| **Age (years)**                      |                        |                |             |
| Mean±SD                              | 69.89±11.56            | 65.73±15.77    | 0.238*      |
| Median (range)                       | 76(46-82)              | 69(15-93)      | 0.264†      |
| Female, n (%)                        | 14(51.85)              | 24(53.33)      | 0.903‡      |
| Time from onset (hours), median (range) | 3(1-24)             | 6(1-24)        | 0.074†      |
| NIHSS score on admission             | 21.22±4.90             | 20.64±5.65     | 0.661*      |
| GCS score on admission               | 9.52±1.76              | 8.51±2.85      | 0.103*      |
| SBP on admission (mm Hg)             | 150.11±26.79           | 145.04±30.72   | 0.480*      |
| DBP on admission (mm Hg)             | 87.78±15.98            | 86.42±18.49    | 0.753*      |
| Serum glucose on admission (mmol/L)  | 7.15±2.20              | 8.39±3.06      | 0.070*      |
| **Risk factors, n (%)**              |                        |                |             |
| Hypertension                         | 10(37.04)              | 25(55.56)      | 0.128‡      |
| Diabetes mellitus                    | 5(16.13)               | 15(33.33)      | 0.174‡      |
| Dyslipidemia                         | 6(22.22)               | 8(17.78)       | 0.645‡      |
| Coronary heart disease               | 6(22.22)               | 7(14.89)       | 0.476‡      |
| Atrial fibrillation                  | 20(74.07)              | 24(53.33)      | 0.081‡      |
| Rheumatic heart disease              | 4(14.81)               | 11(24.44)      | 0.330‡      |
| Current smoking                      | 9(33.33)               | 10(22.22)      | 0.300‡      |
| Alcohol consumption                  | 3(11.11)               | 8(17.78)       | 0.447‡      |
| Previous all strokes/TIA             | 9(33.33)               | 11(24.44)      | 0.415‡      |
| Previous IS                          | 8(29.63)               | 8(17.78)       | 0.242‡      |
| Previous ICH                         | 1(3.70)                | 3(6.67)        | 0.595‡      |
| Previous TIA                         | 0(0)                   | 0(0)           | —           |
| **Stroke in dominant hemisphere, n(%)** | 17(62.96)            | 27(60.00)      | 0.803‡      |
| **TOAST classification, n(%)**       |                        |                | 0.621‡      |
| Large-artery atherosclerosis         | 5(18.52)               | 8(17.78)       |             |
| Cardio-embolism                      | 20(74.07)              | 29(64.44)      |             |
### Table 3. In-hospital treatment, stroke-related complication and outcomes of LHI patients before and after PSM

| Etiology                        | Before PSM | After PSM |
|---------------------------------|------------|-----------|
| Other determined etiology       | 1(3.70)    | 3(6.67)   |
| Undetermined etiology           | 1(3.70)    | 5(11.11)  |

**Abbreviations:** PSM = propensity score matching; ST = standard therapy; SBP = systolic blood pressure; DBP = diastolic blood pressure; NIHSS = National Institutes of Health Stroke Scale; GCS = Glasgow Coma Scale; TIA = transit ischemic attack; IS = ischemic stroke; ICH = intracerebral hemorrhage.

*Student t test. † Mann–Whitney U test. ‡ χ² test.
| Variables                        | Unmatched                  | PS-matched                |      |      |      |      |
|---------------------------------|----------------------------|---------------------------|------|------|------|------|
|                                 | Amantadine (n=31)          | ST (n=127)                |      |      |      |      |
|                                 | St                             | 4(3.15)                   | 0.735| 1(3.70) | 3(6.67) | 1.000 |
|                                 | Mechanical ventilation       | 6(4.72)                   | 1.000| 1(3.70) | 5(11.11) | 0.509 |
|                                 | Osmotic agents               | 110(86.61)                | 0.450| 26(96.30) | 42(93.33) | 1.000 |
| Complications, n (%)            |                             |                           |      |      |      |      |
| Brain edema                     | 29(93.55)                   | 40(31.50)                 | 0.001| 26(96.30) | 41(91.11) | 0.720 |
| Hemorrhagic transformation      | 14(45.16)                   | 31(24.41)                 | 0.022| 13(48.15) | 13(28.89) | 0.100 |
| Seizures                        | 4(12.90)                    | 11(8.66)                  | 0.703| 4(14.81) | 7(15.56) | 1.000 |
| Pneumonia                       | 26(83.87)                   | 81(63.78)                 | 0.032| 23(85.19) | 42(93.33) | 0.472 |
| Gastrointestinal bleeding       | 6(19.35)                    | 22(17.32)                 | 0.791| 6(22.22) | 6(13.33) | 0.514 |
| Acute renal failure             | 7(22.58)                    | 15(11.81)                 | 0.206| 6(22.22) | 8(17.78) | 0.645 |
| Outcomes, n (%)                 |                             |                           |      |      |      |      |
| In-hospital death               | 3(9.68)                     | 27(21.26)                 | 0.132| 2(7.41) | 14(31.11) | 0.019 |
| 3-month mortality               | 9(29.03)                    | 51(40.16)                 | 0.228| 7(25.93) | 25(55.56) | 0.008 |
| 3-month unfavorable outcome     | 19(61.29)                   | 74(58.27)                 | 0.832| 16(59.26) | 32(71.11) | 0.184 |

Abbreviations: ST= standard therapy; PS= propensity score

Table 4. Multivariable analysis for the main outcomes of LHI patients treated with amantadine or not
Variables

|                  | Unmatched |               | PS-matched |               |
|------------------|-----------|---------------|------------|---------------|
|                  | OR        | P value       | OR         | P value       |
| Death in-hospital* | 0.143(0.034-0.605) | 0.008 | 0.113(0.020-0.635) | 0.013 |
| 3-month mortality# | 0.214(0.077-0.598) | 0.003 | 0.176(0.053-0.586) | 0.005 |
| 3-month unfavorable outcomes^ | 0.501(0.192-1.309) | 0.158 | 0.344(0.105-1.126) | 0.078 |

Abbreviations: PS= propensity score

Figures in parentheses are 95% confidence intervals (CI).

* Adjusted for age, sex, baseline NIHSS score and serum glucose on admission.

# Adjusted for age, sex, baseline NIHSS score.

^ Adjusted for age, sex, baseline NIHSS score and vascular risk factors (history of hypertension).

Figures

Figure 1

Flow diagram of included and excluded patients.
Figure 2

3-month survival curves for LHI patients treated with amantadine or not (after PSM).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Supplementarymaterial.docx